Ozempic is no longer just a diabetes drug or a weight-loss trend. It’s the centerpiece of a growing $157 billion market. Behind the scenes, a global patent race is quietly reshaping the future of metabolic health. The question now isn’t just who’s prescribing it, but who’s securing the rights to what comes next.
